NCT06031233 2026-03-30
MINUTE
Isala
Phase 4 Recruiting
Clinical Trials
18 trialsNCT02844322 2026-02-11
BDH-WM01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT02858804 2026-02-11
BDH-MCL01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT07355699 2026-01-21
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Beijing Tongren Hospital
Phase 4 Recruiting
NCT07270835 2025-12-08
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 4 Recruiting
NCT04989491 2024-08-19
REPLY
University Hospital, Strasbourg, France
Phase 4 Recruiting
NCT06134284 2024-06-11
Clinical Study of OR for Second-line Treatment of Refractory MZL
Ningbo No. 1 Hospital
Phase 4 Recruiting
NCT06410833 2024-05-16
BRRPJS
Peking Union Medical College Hospital
Phase 4 Recruiting
NCT00198978 2023-03-20
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Goethe University
Phase 4 Completed
NCT02752815 2022-12-05
Reduced Chemotherapy in Low Risk DLBCL
Ruijin Hospital
Phase 4 Unknown
NCT00199082 2022-08-19
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
Goethe University
Phase 4 Completed
NCT01295151 2016-11-02
SWITCH
University of Leeds
Phase 4 Completed
NCT01358253 2014-05-20
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Ruijin Hospital
Phase 4 Completed
NCT01593332 2012-05-08
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
Mashhad University of Medical Sciences
Phase 4 Completed
NCT00199004 2010-08-23
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Johann Wolfgang Goethe University Hospital
Phase 4 Completed
NCT01124526 2010-05-17
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
Asociacion Espanola de Hematologia y Hemoterapia
Phase 4 Completed
NCT00797810 2009-09-15
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
University of Bologna
Phase 4 Unknown
NCT00131313 2005-08-18
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
East Valley Hematology and Oncology Medical Group
Phase 4 Unknown